AlgiPharma has been awarded up to NOK 10 million from the Norwegian Research Council for the project “Novel alginate oligomer products for enhanced delivery across mucosal barriers (Mucos-ALG)”.
About Philip Rye
This author has yet to write their bio.Meanwhile lets just say that we are proud Philip Rye contributed a whooping 17 entries.
Entries by Philip Rye
Hilde Morris has recently been appointed to replace our outgoing clinical director.
AlgiPharma collaboration wins Cardiff University’s prestigious Medical Innovation Award
AlgiPharma Announces $4 Million Award from Cystic Fibrosis Foundation Therapeutics to Advance Clinical Development of OligoG.
AlgiPharma now features on the Cystic Fibrosis Foundation (CFF) drug development pipeline
AlgiPharma secures new license agreement with NTNU for exclusive global rights.
AlgiPharma granted Orphan Drug designation by FDA
Phone: +47 67545770